Johnson & Johnson (NYSE:JNJ) had its price target boosted by equities researchers at Jefferies Group LLC from $157.00 to $160.00 in a research note issued to investors on Monday, October 16th. The firm presently has a “buy” rating on the stock. Jefferies Group LLC’s price objective points to a potential upside of 12.85% from the stock’s previous close. Jefferies Group also issued estimates for Johnson & Johnson’s FY2017 earnings at $7.27 EPS, FY2018 earnings at $8.18 EPS, FY2019 earnings at $8.96 EPS, FY2020 earnings at $9.69 EPS and FY2021 earnings at $10.58 EPS.
JNJ has been the topic of a number of other research reports. UBS AG restated a “buy” rating and set a $148.00 price objective (up previously from $136.00) on shares of Johnson & Johnson in a research report on Wednesday, July 19th. Goldman Sachs Group, Inc. (The) downgraded shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and increased their price objective for the company from $125.00 to $130.00 in a research report on Wednesday, September 20th. BMO Capital Markets restated a “buy” rating and set a $145.00 price objective on shares of Johnson & Johnson in a research report on Friday, September 1st. Alembic Global Advisors cut shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating in a report on Friday, July 21st. Finally, Morgan Stanley upped their target price on shares of Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, July 5th. Four investment analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $143.70.
Johnson & Johnson (JNJ) traded down 0.02% on Monday, reaching $141.78. The company’s stock had a trading volume of 5,140,654 shares. The company has a market cap of $380.54 billion, a P/E ratio of 24.66 and a beta of 0.78. The stock’s 50 day moving average price is $135.26 and its 200 day moving average price is $131.38. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $144.35.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.68%. The company had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. During the same quarter in the previous year, the company earned $1.68 earnings per share. Johnson & Johnson’s quarterly revenue was up 10.3% on a year-over-year basis. Equities research analysts forecast that Johnson & Johnson will post $7.28 earnings per share for the current year.
WARNING: “Jefferies Group LLC Boosts Johnson & Johnson (JNJ) Price Target to $160.00” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2017/10/28/johnson-johnson-jnj-given-new-160-00-price-target-at-jefferies-group-llc.html.
Hedge funds have recently bought and sold shares of the stock. Harding Loevner LP purchased a new position in Johnson & Johnson during the 2nd quarter valued at about $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its position in Johnson & Johnson by 29.9% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares during the period. Lenox Wealth Advisors Inc. increased its position in Johnson & Johnson by 0.6% during the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after purchasing an additional 5 shares during the period. Mountain Capital Investment Advisors Inc purchased a new position in Johnson & Johnson during the 2nd quarter valued at about $124,000. Finally, Harel Insurance Investments & Financial Services Ltd. increased its position in Johnson & Johnson by 241.0% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock valued at $149,000 after purchasing an additional 841 shares during the period. 65.89% of the stock is currently owned by institutional investors.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.